[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636087":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"International Peace Maternity and Child Health Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IVIG","EXPERIMENTAL","Drug: intravenous immunoglobulin\n\n1 g\u002Fkg\u002Fday for the first 2 days, 0.5 g\u002Fkg\u002Fday for next 3 days (total does 3.5 g\u002Fkg), repeatable if necessary.",[13],"Drug: intravenous immunoglobulin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","intravenous immunoglobulin","1 g\u002Fkg\u002Fday for the first 2 days, 0.5 g\u002Fkg\u002Fday for next 3 days (total does 3.5 g\u002Fkg), repeatable if necessary.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Fu Xuemei","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+86 18017313931","fxmzj2004@163.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Li Dan","+86 18814100771","lidan910327@126.com",[35],{"facility":5,"status":36,"city":37,"state":20,"zip":20,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Shanghai","China","CN",{"type":41,"coordinates":42},"Point",[43,44],121.45806,31.22222,{"lat":44,"lon":43},[47],{"name":48,"role":27,"phone":49,"phoneExt":50,"email":51},"Peng aiping","+86 021 64070434","50407","gfykyll@163.com",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100636087","phase-2-effects-of-ivig-for-bpd-in-preterm-infant-born-at-28-weeks-and-below-100636087",false,"NCT07561125","Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below","The Short-term and Long-term Effects of IVIG for Bronchopulmonary Dysplasia in Preterm Infant Born at 28 Weeks and Below","Inclusion Criteria:\n\n* Gestational age ≤ 28 weeks + 6 days\n* Admission within 24 hours after birth.\n* Infants show a suspicion of BPD, the diagnosis is suspected based on the following clinical manifestations and chest X-ray findings.\n\nClinical manifestations: Respiratory symptoms such as tachypnea (rapid breathing) and cyanosis, requiring respiratory support (including invasive, non-invasive, or oxygen therapy) to maintain oxygen saturation.\n\nChest X-ray: Findings include increased bilateral lung markings or ground-glass opacities, and diffuse increased density in both lungs. Other possible causes such as infection or heart disease should be ruled out.\n\n• A normal full-term newborn without a history of severe lung diseases, birth asphyxia, hypoxic-ischemic encephalopathy or other conditions that may affect the development of the respiratory, nervous and other systems.\n\nExclusion Criteria:\n\n* Major congenital anomalies(e.g., congenital heart disease, congenital craniocerebral deformity, congenital structural abnormality of respiratory system, congenital hereditary metabolic disease)\n* Chromosomal defects (e.g., trisomy 13, 18, 21)\n* Severe intracranial hemorrhage\n* Multiple organ failure\n* With severe lung infections\n* Other circumstances that the investigator determines are not suitable for participation in this study",true,"ALL","1 Day","10 Weeks",{"count":66,"type":67},29,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g\u002Fkg\u002Fday for the first 2 days, 0.5 g\u002Fkg\u002Fday for next 3 days (total does 3.5 g\u002Fkg), repeatable if necessary.",[73],"Bronchopulmonary Dysplasia","2026-04-26",{"date":76,"type":77},"2026-05-01","ACTUAL",{"date":79,"type":67},"2026-04",{"date":81,"type":67},"2029-09",{"name":5,"class":6},1]